Aug 5, 2020 7:00 am EDT Castle Biosciences to Present at the Canaccord Genuity 40th Annual Growth Conference
Jul 27, 2020 7:00 am EDT Castle Biosciences to Release Second Quarter 2020 Financial Results and Host Conference Call on Monday, August 10, 2020
Jul 15, 2020 8:42 am EDT Castle Biosciences Announces Publication of Clinical Utility, Long-Term Outcomes Data and Meta-Analysis for DecisionDx-UM for Patients with Uveal Melanoma
Jul 9, 2020 8:17 am EDT Second Systematic Review and Meta-Analysis Published Demonstrating DecisionDx-Melanoma as Independent Predictor of Recurrence, Distant Metastasis and Overall Survival in Cutaneous Melanoma
Jul 2, 2020 5:00 pm EDT Castle Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock
Jun 24, 2020 9:33 pm EDT Castle Biosciences Announces Pricing of $74.0 Million Public Offering of Common Stock
Jun 22, 2020 4:33 pm EDT Castle Biosciences Announces Proposed Underwritten Public Offering of Common Stock
May 22, 2020 7:00 am EDT Castle Biosciences Announces Change of Location of Annual Meeting of Stockholders to Be Held June 4, 2020
May 19, 2020 7:00 am EDT New Data Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-SCC Test Results on Patient Management Decisions
